Harmony Biosciences在2025年第四季度的盈利预期未达预期，但收入超出预期，在分析师评级褒贬不一和股价低迷的情况下，重申了2026年的指引。 Harmony Biosciences missed earnings estimates in Q4 2025 but beat revenue forecasts, reaffirming 2026 guidance amid mixed analyst ratings and low stock price.

和谐生物科学组织报告说,2025年的Q4收入为每股0.38美元,没有达成84美元的共识,尽管收入达到2.4378亿美元,超过估计数,逐年上升21.1%。 Harmony Biosciences reported Q4 2025 earnings of $0.38 per share, missing the $0.84 consensus, though revenue hit $243.78 million, surpassing estimates and rising 21.1% year-over-year. 在WAKIX销售的推动下,该公司重申其2026年净收入10亿至10.4亿美元的指导。 The company reaffirmed its 2026 net revenue guidance of $1.0–1.04 billion, driven by WAKIX sales. 分析师提供好坏参半的评分:UBS将其目标降至36美元, 并保持“中立”, Analysts offered mixed ratings: UBS lowered its target to $36 and kept "neutral," Bank of America cut to "underperform" with a $28 target, while HC Wainwright maintained a "buy" with a $55 target. 股票以28.31美元关闭,接近52周的最低点,机构所有权为86.23%,内幕销售有记录。 The stock closed at $28.31, near its 52-week low, with institutional ownership at 86.23% and insider sales noted.